An observational study in Pulmonary Embolism (PE) and Snake Envenomation, sponsored by Younes Oujidi. Completed at 1 site in Morocco. Open to female participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-06-06.
Sponsored by Younes Oujidi · Observational
Viper envenomation constitutes a medical emergency predominantly occurring in rural regions, where specific viper species are endemic, with their distribution influenced by climatic variations. The literature describes numerous complications associated with viper bites, including neurological disturbance, hematological abnormalities, and irreversible renal failure.
We report the case of a 65-year-old female patient admitted to the intensive care unit for viper envenomation characterized by extensive local edema. Diagnostic investigations, including laboratory tests and imaging studies, revealed the presence of a bilateral pulmonary embolism. The patient was subsequently treated with antivenom therapy, followed by initiation of low molecular weight heparin. Despite the recognized high risk of viper envenomation described in the literature, the patient experienced an uncomplicated clinical course and was discharged in stable condition with no further complications.
832 studies on the registry are indexed under Pulmonary Embolism; 171 are open to participants now.
This study's enrollment of 1 is below the median of 361 across 366 observational studies indexed under Pulmonary Embolism.
Browse Pulmonary Embolism studies →This is the only study on the registry with Younes Oujidi as lead sponsor.
Counted across the registry records on this site, refreshed daily.
People aged above 18years, developing a pulmonary embolism after snake bites
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Evolution of hematological blood test during the ICU stay
Time frame: From January 2025 to May 2025
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jan 2025 to primary completion in Jan 2025, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.